Avalo Therapeutics, Inc.AVTXNASDAQ
Loading
Operating Cash Flow Growth Under PressureDecelerating
Percentile Rank33
Studio
Year-over-Year Change

Year-over-year operating cash flow growth rate

Percentile
P33
Within normal range
vs 2Y Ago
-1x
Contraction
Streak
2 yr
Consecutive declineDecelerating
PeriodValue
2024-59.90%
2023-14.69%
202262.27%
2021-74.87%
2020-111.87%
2019-511.69%
2018-124.99%
2017185.91%
2016-43.39%
201534.51%